Bevacizumab Biosimilars Market Report 2026

The bevacizumab biosimilars market size has grown strongly in recent years. It will grow from $1.64 billion in 2025 to $1.77 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to patent expiry of reference bevacizumab, rising cancer prevalence, demand for cost-effective biologics, government incentives for biosimilars, advancements in recombinant DNA technology.

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing biosimilar approvals, expansion in emerging markets, integration of AI in drug development, growing preference for outpatient oncology care, strategic collaborations among pharma companies. Major trends in the forecast period include increased adoption of biosimilars in oncology, cost-effective treatment alternatives, rising regulatory approvals for biosimilars, expansion of hospital and retail pharmacy networks, growth of specialty cancer treatment centers.

The rising prevalence of cancer is expected to drive the growth of the bevacizumab biosimilars market. Cancer incidence, defined as the number of new cases within a specific population over a given period, continues to rise globally. Bevacizumab, a biologic that inhibits tumor angiogenesis, helps shrink tumors and slow cancer progression while maintaining comparable efficacy and safety to reference biologics for advanced non-small cell lung cancer, metastatic colorectal cancer, and other malignancies. For instance, in October 2025, NHS England reported 354,820 new cancer diagnoses in 2023, an increase of 8,605 cases compared with 2022. This growing cancer burden is driving demand for cost-effective bevacizumab biosimilars.

Major companies in this market are focusing on next-generation, indication-expanded formulations to enhance accessibility and broaden clinical applications. For example, in March 2024, Dr. Reddy’s Laboratories, India, launched Versavo (bevacizumab) in the UK, offering oncology treatments including colorectal, lung, glioblastoma, renal, cervical, ovarian, and breast cancers at more affordable costs while maintaining standard dosing in 100 mg and 400 mg vials.

In February 2024, Biocon Biologics Ltd, India, partnered with Sandoz Australia to expand access to oncology biosimilars such as bevacizumab and trastuzumab, leveraging Sandoz’s marketing and distribution network to strengthen its global commercial footprint.

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA.

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bevacizumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the bevacizumab biosimilars market by increasing import costs of raw materials, biologic components, and manufacturing equipment, leading to higher production expenses and potential delays in product availability. The oncology drug segments, particularly biosimilars like Mvasi and Zirabev, and regions such as North America and Europe are most affected due to heavy import reliance. However, tariffs have also encouraged local production and sourcing diversification, potentially boosting domestic manufacturing capacities and innovation in biosimilar development.

The bevacizumab biosimilars market research report is one of a series of new reports that provides bevacizumab biosimilars market statistics, including bevacizumab biosimilars industry global market size, regional shares, competitors with a bevacizumab biosimilars market share, detailed bevacizumab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the bevacizumab biosimilars industry. This bevacizumab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bevacizumab biosimilars are medications that closely resemble the reference biologic drug bevacizumab. They work by inhibiting the growth of new blood vessels in tumors, thereby slowing tumor progression.

The main bevacizumab biosimilar products include Avastin, Mvasi, Zirabev, Aybintio, and others. Avastin is the original brand of bevacizumab and acts as an anti-angiogenic therapy to prevent new blood vessel formation. These biosimilars are distributed through hospital pharmacies, online pharmacies, retail pharmacies, and other channels. They are used to treat conditions such as colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

The bevacizumab biosimilars market consists of sales of byvasda, cizumab, alymsys, bevax, and cyramza. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.